SES GS Awarded U.S. Government Satellite Solutions Contract
SES announced that the U.S. General Services Administration’s (GSA) Future Satellite Communications Service Acquisition (FCSA) program has awarded SES Government Solutions, a wholly-owned subsidiary of SES, a spot on the Complex Commercial Satellite Communications Solutions contract (CS3).
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171102005248/en/
SES GS Awarded U.S. Government Satellite Solutions Contract (Photo: Business Wire)
“We are very proud to be part of the CS3 team of awardees,” said Pete Hoene, President and CEO of SES Government Solutions. “CS3 gives the U.S. Government and its agencies another contract vehicle to leverage the uniquely scalable and secure end-to-end managed-services SES Government Solutions provides. It will allow the U.S. Government to take advantage of our most innovative offerings including high throughput connectivity on our multi-orbit satellite fleet.”
Industry awardees will be able to bid on opportunities with a budget ceiling of $2.5 billion. The Indefinite Delivery/Indefinite Quantity (ID/IQ) contract vehicle has a ten-year period of performance consisting of a five-year base term plus a three-year and two-year option.
CS3 helps to ensure that critical government communications are delivered using the top capabilities available in the market. According to the General Services Administration, CS3 awards were given to the highest technically rated offerors with a fair and reasonable price. Complex solutions can include any combination of fixed and/or mobile satellite services, service enabling authorizations, components, and ancillary equipment such as terminals, teleports, and peripherals.
Follow us on:
About SES Government Solutions
SES Government Solutions, a subsidiary of global satellite operator SES, is exclusively focused on meeting the satellite communications needs of the U.S. Government. Leveraging more than four decades of experience in the government SATCOM market, SES Government Solutions offers robust and secure end-to-end satellite communications solutions. Further information can be found at www.ses-gs.com
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com
For further information please contact:
Markus Payer, +352 710 725 500
Corporate Communications & PR
SES Government Solutions
Natalia Kossobokova, +1-703-646-7231
Marketing & Communications
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Norsk Titanium Announces Strategic Investment from Rose Park Advisors’ Disruptive Innovation Fund20.11.2017 16:00 | Tiedote
Norsk Titanium, the metal additive manufacturing pioneer, today announced it has closed on a significant investment from Rose Park Advisors’ Disruptive Innovation Fund, known for its application of the theory of Disruptive Innovation® developed by co-founder Clayton Christensen. Terms of the investment were not released. “This strategic investment from Rose Park Advisors underscores the ability of Norsk Titanium’s Rapid Plasma Deposition™ (RPD™) technology to disrupt the metal manufacturing processes,” said Norsk Titanium Chairman of the Board John Andersen, Jr. “There are few people that are as widely respected by more business leaders than Dr. Christensen. We are humbled by his recognition of our technology and business model.” “Our strong relationships in commercial aerospace have allowed us to improve our processes and create a platform technology under the watchful eyes
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential20.11.2017 16:00 | Tiedote
Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients. “Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas,“ said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compoun
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 11:43 | Tiedote
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 11:29 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 11:00 | Tiedote
(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 11:00 | Tiedote
Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme